Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY
Veröffentlicht am: 17.11.2026 um 12:44 Uhr | dpa, AD HOC NEWS
Original-Research: Pentixapharm Holding AG - from NuWays AG
17.11.2026 / 12:44 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS
Group.
The issuer is solely responsible for the content of this research. The
result of this research does not constitute investment advice or an
invitation to conclude certain stock exchange transactions.
---------------------------------------------------------------------------
Classification of NuWays AG to Pentixapharm Holding AG
Company Name: Pentixapharm Holding AG
ISIN: DE000A40AEG0
Reason for the research: Update
Recommendation: BUY
Target price: EUR 7.20
Target price on sight of: 12 months
Last rating change:
Analyst: Simon Keller
Q3 review: an extra dose of upside; chg.
Pentixapharm's Q3 update reinforces the BUY case ahead of PANDA's start and
potential partnering in 2027. Regulatory preparations have advanced, new
oncology data strengthen the opportunity beyond primary aldosteronism (PA),
and the convertible extension provides greater financial flexibility. In
detail:
PANDA's delayed start should have limited implications for long-term value.
First-patient enrolment is now expected in Q1 2027, versus H2 2026
previously. Regulatory preparations have advanced: the FDA raised no
concerns regarding the final protocol, central ethics approval was received
in October and more than ten US sites have been selected for final contract
negotiations. The subsequent study timetable should remain largely
unchanged, with US launch still expected in 2030 (eNuW). Recruitment pace
across the planned c. 325-patient study will therefore be more important for
assessing the commercial timeline than the first-patient date alone. Early
evidence of sustained recruitment should strengthen confidence in execution
and support the shares.
Commercial partnering is expected around summer 2027 (eNuW: Q2), offering a
potential re-rating catalyst. An agreement should provide external
validation of PentixaFor's appeal and access to the commercial
infrastructure needed to convert its diagnostic potential into market
uptake. Potential upfront payments would also help fund further development
and reduce reliance on additional equity. Recruitment progress should
strengthen Pentixapharm's negotiating position by demonstrating that the
programme is advancing towards registrational data.
PENTHERA adds a therapeutic opportunity beyond PA diagnostics. The programme
combines PentixaFor imaging, which identifies disease, with PentixaTher,
which delivers targeted radiation. The aim is to kill blood cancer cells and
prepare the bone marrow for stem-cell transplantation, reducing reliance on
high-dose chemotherapy and its associated toxicity. The initial focus is
acute myeloid leukaemia (AML) and multiple myeloma. The planned Phase I/II
study already has FDA clearance, providing a development route towards a
combined diagnostic and therapeutic franchise.
The initial market offers meaningful scale. Around 25,000 stem-cell
transplants are performed annually for AML and multiple myeloma across
Europe and the US, each requiring preparatory treatment. This provides a
defined market for PENTHERA's targeted approach. The commercial opportunity
spans both imaging and treatment, allowing partnerships covering either
asset or the combined offering. This therapeutic potential remains outside
our PA-based valuation, leaving clinical progress as additional upside.
Early patient data should strengthen the basis for an oncology development
partnership. An imaging study in multiple myeloma has already shown that
PentixaFor detected approximately three times as many cancer lesions as
standard imaging (FDG PET). A separate hospital-led study has completed
treatment of acute leukaemia patients with PentixaTher, with initial results
expected in December 2026. These should provide early evidence on safety and
activity against cancer, giving potential partners a clearer basis for
assessing the therapeutic asset. Pentixapharm's own PENTHERA trial has yet
to start, with PANDA remaining the priority for clinical investment. A
development partner offers an attractive way to finance and execute the next
study, sharing costs and responsibilities while creating scope for upfront
funding well before product sales.
Q3 also demonstrates the benefit of the smaller organisational cost base.
Personnel expenses fell to EUR 0.9m, with an EBITDA loss of EUR 2.4m, a net loss
of EUR 2.5m and operating cash outflow of c. EUR 2.3m. The latter equates to an
annualised run-rate of c. EUR 9.2m before PANDA enrolment ramps up. Confirmed
FY26 net-loss guidance of c. EUR 13m compares with EUR 21.6m previously. The
improvement includes c. EUR 3m of PANDA expenditure partly shifting into 2027,
lower personnel expenses and c. EUR 3.7m mainly from eliminated amortisation
following the BaFin corrections. Clinical spending should increase in 2027,
supported by a leaner organisation. Meanwhile, the extension of its existing
convertible bond strengthens Pentixapharm's position in partnering talks,
pushing repayment to 2030. Funding is expected to last into 2028, excluding
partnership proceeds.
Clinical execution and partnering remain the next opportunities for a
re-rating. The core PentixaFor opportunity is unchanged, with broader PA
screening supporting demand for a scalable alternative to invasive
subtyping. Oncology progress offers additional upside outside the existing
valuation. Reiterate BUY with an unchanged rNPV-based PT of EUR 7.20.
READ RESEARCH UPDATE
You can download the research here:
https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&u=1a2608b756d8baaa54289da68f84e559
For additional information visit our website:
https://www.nuways-ag.com/research
Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss
bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben
analysierten Unternehmen befindet sich in der vollständigen Analyse.
++++++++++
---------------------------------------------------------------------------
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
View original content:
https://eqs-news.com/?origin_id=5dbf7c72-e27a-11f1-b46d-066675bb9927&lang=en
---------------------------------------------------------------------------
2436742 17.11.2026 CET/CEST
Disclaimer...
de | DE000A40AEG0 | ORIGINAL-RESEARCH | boerse | 70526395 |
